BRIGHTLINE-1
12 Apr 2022
Trial Summary
Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcom
Acronym:
NCT05218499
ACTRN/NCT /ethics:
NCT04047862
Scientific title:
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma
Sponsor / Cooperative group:
Boehringer Ingelheim
Trial & Patient Characteristics
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II; Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Liposarcoma |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2022-03-25 |
| Anticipated End Date | 2024-03-01 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Nimit Singhal |
| Recruitment Status | Recruiting |